Sonoma Pharmaceuticals (SNOA) Total Non-Current Liabilities (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Total Non-Current Liabilities of $5.3 million for Q1 2026, up 28.04% year-over-year from $4.1 million in Q1 2025, and up 12.17% quarter-over-quarter from $4.7 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 28.04% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (up 28.04% YoY), while the FY2026 annual figure was $5.3 million, up 28.04% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $5.3 million, up from $4.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $6.3 million in Q1 2022, with the low at $3.3 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $4.1 million (2025), against an average of $4.4 million.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities tumbled 36.31% in 2023, then surged 38.62% in 2025.
- Sonoma Pharmaceuticals' Total Non-Current Liabilities stood at $4.3 million in 2022, then fell by 21.93% to $3.3 million in 2023, then grew by 12.8% to $3.8 million in 2024, then advanced by 25.62% to $4.7 million in 2025, then grew by 12.17% to $5.3 million in 2026.
- Business Quant data shows SNOA's Total Non-Current Liabilities at $5.3 million in Q1 2026, $4.7 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.89 Mn |
| Mar 31, 2026 | 5.30 Mn |
| Dec 31, 2025 | 4.73 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 5.29 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Sep 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 4.29 Mn |
| Mar 31, 2023 | 4.02 Mn |
| Dec 31, 2022 | 4.27 Mn |
| Sep 30, 2022 | 3.93 Mn |
| Jun 30, 2022 | 5.27 Mn |
| Mar 31, 2022 | 6.31 Mn |
| Dec 31, 2021 | 4.43 Mn |
| Sep 30, 2021 | 4.71 Mn |